Skip to main content
Springer logoLink to Springer
. 2021 Mar 23;81(5):619. doi: 10.1007/s40265-021-01500-6

Correction to: Lonafarnib: First Approval

Sohita Dhillon 1,
PMCID: PMC8052252  PMID: 33755935

Correction to: Drugs (2020) 81(2):283–289 10.1007/s40265-020-01464-z

The article Lonafarnib: First Approval, written by Sohita Dhillon, was originally published electronically in SpringerLink on 15 February 2021 without open access. After publication in volume 81, issue 2, pages 283–289 Eiger BioPharmaceuticals, requested that the article be Open Choice to make the article an open access publication. Post-publication open access was funded by Eiger BioPharmaceuticals. This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

The original article has been corrected.


Articles from Drugs are provided here courtesy of Springer

RESOURCES